Päävalikko

Growth in health technology

Research focuses on health technology R&D projects with the objective of commercializing new solutions for health care professionals. The common denominator of the projects is to support the planning of diagnosis and treatment in general serious diseases.

Our goal is to build growth paths from these new openings alongside the current products of the Revenio Group.

Asthma is the most common chronic disease in children

More than 300 million people globally suffer from asthma. Diagnosing asthma can be difficult, particularly in children. One in five children have asthma-like symptoms, and one in ten is diagnosed with asthma.

Assessment of asthma is difficult, particularly in small children, and is largely based on the physician’s subjective viewpoint. The Ventica® system is designed to assist in the diagnosis of asthma and monitoring its control in children aged 1-5 years. The measurement is done easily at night, while the child is asleep at home. The analysis software examines the fluctuation of the respiratory rate at rest and provides the physician with simple, objective report to support clinical assessment.

The goal of Revenio is to provide a solution for routine clinical use. There are no competing technologies, and the market's interest in the product is high. The Ventica® system is now available in Europe and Australia.

Image

Melanoma is the fastest-growing cancer

Skin cancers and their precursors are increasing rapidly throughout the world. Two to three million cases of melanoma are diagnosed worldwide each year as a consequence of continuously increasing exposure to UV radiation as well as an aging population.

With Cutica®, the Revenio hyperspectral camera system under development, changes imperceptible to the eye as well as their boundaries can be detected. This will help the dermatologist to plan the surgical site of melanoma more accurately, which is especially critical in the area of the head, where melanoma most commonly occurs. It is important to remove the tumor completely in order to avoid repeat surgery. Currently, approximately 50% of skin cancer surgeries have to be repeated.